Hovione announces key patent grants for its large dose DPI

Hovione Technology's TwinMax DPI.

TwinMax enabes delivery of doses up to 100 mg formulated as drug alone or engineered particles.

“We achieved unchallenged patent grants for TwinMax in the US, Europe, Japan, China and other territories. Our patented TwinMax will enable pharmaceutical partners to license them and to develop and take forward to the market new drugs requiring delivery of large lung doses", said Peter Villax, Hovione Technology’s CEO.

TwinMax is an innovative, 2-puff, disposable DPI designed for indications requiring high dose delivery to the lungs. It features a patent-granted design enabling delivery of doses up to 100 mg formulated as drug alone or engineered particles.

“The patient simply needs to perform one use step and the large target dose is delivered from 2 puffs to make delivery comfortable. We have designed an enhanced inhaler engine for large dose delivery, while keeping the overall usability of TwinCaps, the world’s leading disposable inhaler with an experience of 10 years treating patients in Japan”, said Dr João Ventura Fernandes, Hovione Technology’s Director of Technology Development and Licensing.

Hovione Technology’s TwinMax and 8Shot dry powder inhalers are designed to enable safe and effective delivery of large doses to the lung. Featuring patented inhaler technology, TwinMax and 8Shot are compatible with drug doses up to 100 mg and 400 mg respectively, delivered conveniently to patients from multiple inhalations. Our Large Dose DPIs are suitable for inhaled delivery of antibiotics, peptides, anti-virals, vaccines, pain or rescue treatments.